Seagen
Seagen’s breast cancer drug TUKYSA gets UK approval
February 22, 2021Sales and Marketing Cancer, MHRA, Seagen
The MHRA has granted marketing authorisation in the UK for Seagen’s TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, for …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
